Clinical Observation of Sofren Injection and Guanxin Shutong Capsu les for Patients with Restenosis after Coronary Intervention
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
文章评论
摘要:
目的:观察大株红景天注射液与冠心舒通胶囊联合常规疗法治疗冠状动脉介入治疗(PCI)术后再狭窄患者的疗效。方法:选择70例PCI术后再狭窄患者,按随机数字表法分为2组,2组均服用阿司匹林、氯吡格雷及辛伐他汀等常规西药治疗,治疗组加用大株红景天注射液与冠心舒通胶囊治疗。15天为1疗程,治疗2疗程。观察患者治疗前后临床症状及循环血内皮微粒(EMPs)、细胞间黏附分子(sICAM-1)、超氧化物歧化酶(SOD)、丙二醛(MDA) 的变化,6月后行冠状动脉造影复查。结果:治疗组总有效率95.0%,对照组总有效率60.0%,2组总有效率比较,差异有统计学意义( P <0.01)。治疗组胸痛、胸闷、气短、乏力、口干症状积分及总积分均较治疗前减少( P <0.05),对照组胸痛、胸闷症状得到改善( P <0.05),气短、乏力、口干症状无明显改善(P>0.05),2组各项症状积分与总积分比较,差异均有统计学意义 ( P <0.05)。2组SOD、MDA及EMPs、sICAM-1水平与治疗前比较,差异均有统计学意义( P <0.05)。治疗组SOD水平高于对照组,MDA及EMPs、sICAM-1水平均低于对照组,差异均有统计学意义( P <0.05)。治疗组冠状动脉再狭窄发生率7.5%,对照组冠状动脉再狭窄发生率30.0%,2组比较,差异有统计学意义( P <0.05)。治疗组在改善血管内径丢失、管腔面积净获得方面优于对照组。结论:大株红景天注射液与冠心舒通胶囊联合西药的治疗方案可减轻PCI术后患者的心绞痛症状,与单纯西药治疗比较,并无增加不良反应,提高了患者的依从性和生活质量,疗效确切、安全性好,体现了单味中药及复方多途径、多环节、多靶点的治疗优势,对预防和治疗冠心病PCI术后再狭窄有着重要意义。
Abstract:
Objective:To observe the curative effect of Sofren injection and Guanxin Shutong capsules com bined with routine therapy for patients with restenosis after percutaneous coronary intervention(PCI).Methods:Selected 70 cases of patients with restenosis after PCIand divided theminto two groups according to random num ber table.The two groups were given routine western medicine such as aspirin,clopidogrel and sim vastatin orally,while the control group was given Sofren injection and Guanxin Shutong capsules additionally.The treatment for both groups lasted for 2 courses,15 days per course.Observed the changes of clinical symptoms, endothelial microparticles(EMPs)in serum, soluble intercellular adhesion molecule-1(sICAM-1),superoxide dismutase(SOD)and m alonaldehyde(MDA)before and after treatment.A reexamination by coronary angiography was given 6 months later.Results:The total effective rate was 95.0%in the observation group and 60.0%in the control group,difference being significant( P <0.01).The symptomscores of chest pain,chest distress,shortness of breath,hypodynamia and dry mouth as well as the total scores in the observation group were all decreased when compared with those before treatment( P <0.05).The symptoms of chest pain and chest distress in the control group were both improved( P <0.05),and there was no obvious improvements being found in the symptoms of shortness ofbreath,hypodynamia and dry mouth( P >0.05).There were significant differences being found in the comparisons between each symptomscore and the total score( P <0.05).There were significant differences being found in the comparisons of levels of SOD,MDA,EMPs and s ICAM-1 in the two groups with those before treatment( P <0.05).The SOD level in the observation group was higher than that in the control group,and the levels of MDA,EMPs and sICAM-1 were lower than those in the control group,differences being significant( P <0.05).The incidence of coronary restenosis was 7.5%in the observation group and 30.0% in the control group,difference being significant( P <0.05).The observation group was superior to the control group in improving the loss of blood vessel diameter and lumen area net gain.Conclusion:The application of Sofren injection and Guanxin Shutong capsules com bined with the three-level treatment strategy of western medicine can reduce the symptoms of angina pectoris in patients after PCI.Compared with western medicine alone,it does not increase adverse reactions but improves compliance and quality of life of patients.With a significant curative effect and good safety,it em bodies the treatment advantages of single Chinese herbs and the compound prescriptions in multiple paths,sections and target,which is of greatsignificance in prevention and treatmentof coronary heartdiseasewith restenosis afterPCI.